Figures & data
Table 1. Determination of drug and polymers.
Figure 2. Antioxidants activity of CS-PLA NPs, PIC and CS/PLA-PIC NPs with the control of quercitin. (a) DPPH (b) SOD and (c) NO scavenging activities.
![Figure 2. Antioxidants activity of CS-PLA NPs, PIC and CS/PLA-PIC NPs with the control of quercitin. (a) DPPH (b) SOD and (c) NO scavenging activities.](/cms/asset/35e2381e-cab2-4797-acb3-fee375f632be/ianb_a_1422130_f0002_c.jpg)
Figure 3. (A) MTT assay of CS-PLA NPs, PIC and CS/PLA-PIC NPs with (a) HepG2. (b) A549 (c) MCF7 cell lines. (B) LDH activity of CS-PLA NPs, PIC and CS/PLA-PIC NPs with (a) HepG2. (b) A549 (c) MCF7 cell lines.
![Figure 3. (A) MTT assay of CS-PLA NPs, PIC and CS/PLA-PIC NPs with (a) HepG2. (b) A549 (c) MCF7 cell lines. (B) LDH activity of CS-PLA NPs, PIC and CS/PLA-PIC NPs with (a) HepG2. (b) A549 (c) MCF7 cell lines.](/cms/asset/5eb16516-b7c9-49b9-800c-e7caacb89d46/ianb_a_1422130_f0003_c.jpg)
Figure 4. Analysis of DNA isolated from HepG2, A549 and MCF cells incubated with IC30 and IC50 concentration of CS/PLA-PIC NPs for 24 h; cells without treatment (lane C), HepG2 cells treated with 20 µg/ml (lane 1), and 40 µg/ml (lane2), A549 cells treated with 40 µg/ml (lane 1), and 60 µg/ml (lane 2) and MCF7 cells treated with 40 µg/ml(lane 1), and 60 µg/ml(lane 2).
![Figure 4. Analysis of DNA isolated from HepG2, A549 and MCF cells incubated with IC30 and IC50 concentration of CS/PLA-PIC NPs for 24 h; cells without treatment (lane C), HepG2 cells treated with 20 µg/ml (lane 1), and 40 µg/ml (lane2), A549 cells treated with 40 µg/ml (lane 1), and 60 µg/ml (lane 2) and MCF7 cells treated with 40 µg/ml(lane 1), and 60 µg/ml(lane 2).](/cms/asset/5a3796b5-1e7a-450a-b9b2-6c517f705362/ianb_a_1422130_f0004_b.jpg)
Figure 5. Cells stained with AO and EB of CS/PLA-PIC treated HepG2, A549, and MCF cells at 24 h. Cells without treatment (control) HepG2 cells treated with (a) 20 µg/ml, (b) 40 µg/ml and (c) 60 µg/ml. A549 cells treated with (a) 40 µg/ml, (b) 60 µg/ml and (c) 80 µg/ml. MCF7 cells treated with (a) 40 µg/ml, (b) 60 µg/ml and (c) 80 µg/ml.
![Figure 5. Cells stained with AO and EB of CS/PLA-PIC treated HepG2, A549, and MCF cells at 24 h. Cells without treatment (control) HepG2 cells treated with (a) 20 µg/ml, (b) 40 µg/ml and (c) 60 µg/ml. A549 cells treated with (a) 40 µg/ml, (b) 60 µg/ml and (c) 80 µg/ml. MCF7 cells treated with (a) 40 µg/ml, (b) 60 µg/ml and (c) 80 µg/ml.](/cms/asset/8985a7fa-a0df-4451-938d-becfd2edc49e/ianb_a_1422130_f0005_c.jpg)